July 25 (Reuters) - CARsgen Therapeutics 2171.HK:
SEES NET LOSS NOT MORE THAN RMB80 MILLION IN HY
REDUCTION IN LOSS DUE TO CT053 COMMERCIALIZATION AND REDUCED RESEARCH AND DEVELOPMENT
Further company coverage: 2171.HK
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.